Stock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement

Stock Track

02/25

Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.

The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.

This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1135785944"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135785944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135785944?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135785944","market":"sg","top_or_hot":-1,"title":"Stock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement","media":"Stock Track","content":"<p>Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.</p><p>The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.</p><p>This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.</p><p>The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.</p><p>This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"","article_id":"1135785944","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135785944","pubTimestamp":1771984504,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.The decline came after the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"translate_title":"个股追踪|宣布发行2亿美元股票后Vir Biotechnology盘后暴跌5.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1},"content_text":"Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}